Artelo Biosciences, Inc.
NASDAQ Capital MarketTotal Valuation
Artelo Biosciences, Inc. carries a market capitalization of 13,069.00, placing it among publicly traded companies globally. Its enterprise value stands at -9.55M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 13,069.00 |
| Enterprise Value | -9.55M |
Share Statistics
Artelo Biosciences, Inc. currently has 876,032.00 shares outstanding.
| Shares Outstanding | 876,032.00 |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
Artelo Biosciences, Inc. maintains a current ratio of 1.79, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 10.78, indicating elevated leverage, while an interest coverage ratio of -29.21 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.79 |
| Quick Ratio | 1.76 |
| Debt / Equity | 10.78 |
| Debt / EBITDA | -0.06 |
| Interest Coverage | -29.21 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -167.97 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Artelo Biosciences, Inc.'s stock has declined approximately -88.8% over the past 52 weeks. The 50-day moving average sits at - -, while the 200-day moving average is - -.
| Beta (5Y) | N/A |
| 52-Week Price Change | -88.8% |
| 50-Day Moving Average | - - |
| 200-Day Moving Average | - - |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -11.71M, while operating income came in at -11.71M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -11.71M |
| Pretax Income | -13.46M |
| Net Income | -13.46M |
| EBITDA | -11.71M |
| EBIT | -11.71M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
Artelo Biosciences, Inc. holds 10.27M in cash and equivalents against 719,000.00 in total debt, resulting in a net debt position of -9.61M. Total book value stands at -65.97M, with working capital of 4.59M providing operational flexibility.
| Cash & Cash Equivalents | 10.27M |
| Total Debt | 719,000.00 |
| Net Debt | -9.61M |
| Equity (Book Value) | -65.97M |
| Book Value Per Share | N/A |
| Working Capital | 4.59M |
Cash Flow
Artelo Biosciences, Inc. produced -8.11M in operating cash flow over the past twelve months.
| Operating Cash Flow | -8.11M |
| Capital Expenditures | N/A |
| Free Cash Flow | -8.11M |
| FCF Per Share | N/A |
Scores
Artelo Biosciences, Inc. posts an Altman Z-Score of -11.98, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -11.98 |